The Johnson & Johnson (JNJ) Position Decreased by Schwartz Investment Counsel Inc.

The Johnson & Johnson (JNJ) Position Decreased by Schwartz Investment Counsel Inc.

Schwartz Investment Counsel Inc. reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 3.6% during the third quarter, Holdings Channel reports. The firm owned 6,750 shares of the company’s stock after selling 250 shares during the period. Schwartz Investment Counsel Inc.’s holdings in Johnson & Johnson were worth $797,000 at the end of the most recent reporting period.

Several other institutional investors also recently added to or reduced their stakes in the stock. Americafirst Capital Management LLC bought a new position in Johnson & Johnson during the second quarter worth $101,000. Tuttle Tactical Management LLC bought a new position in Johnson & Johnson during the second quarter worth $103,000. Lenox Wealth Management Inc. raised its position in Johnson & Johnson by 24.3% in the second quarter. Lenox Wealth Management Inc. now owns 972 shares of the company’s stock worth $118,000 after buying an additional 190 shares during the period. Thomas J. Herzfeld Advisors Inc. raised its position in Johnson & Johnson by 221.2% in the second quarter. Thomas J. Herzfeld Advisors Inc. now owns 1,002 shares of the company’s stock worth $122,000 after buying an additional 690 shares during the period. Finally, NCM Capital Management Group Inc. bought a new position in Johnson & Johnson during the second quarter worth $127,000. Institutional investors and hedge funds own 64.03% of the company’s stock.

Shares of Johnson & Johnson (NYSE:JNJ) traded down 0.44% during mid-day trading on Thursday, hitting $114.20. The stock had a trading volume of 5,540,831 shares. The stock has a 50 day moving average of $114.60 and a 200-day moving average of $118.18. The stock has a market capitalization of $310.68 billion, a P/E ratio of 20.05 and a beta of 0.72. Johnson & Johnson has a 52 week low of $94.28 and a 52 week high of $126.07.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 14th. Investors of record on Tuesday, February 28th will be issued a dividend of $0.80 per share. The ex-dividend date of this dividend is Friday, February 24th. This represents a $3.20 annualized dividend and a yield of 2.80%. Johnson & Johnson’s payout ratio is presently 56.64%.

Several equities research analysts recently issued reports on JNJ shares. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $117.64 price objective for the company in a research note on Tuesday, November 29th. Credit Suisse Group AG reissued a “hold” rating on shares of Johnson & Johnson in a research note on Tuesday, December 20th. RBC Capital Markets set a $133.00 price objective on Johnson & Johnson and gave the stock a “buy” rating in a research note on Wednesday, November 9th. Zacks Investment Research downgraded Johnson & Johnson from a “hold” rating to a “sell” rating in a research note on Wednesday, September 28th. Finally, Argus reissued a “buy” rating and issued a $145.00 price objective on shares of Johnson & Johnson in a research note on Friday, October 21st. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $122.22.

In related news, Director Charles Prince bought 875 shares of the company’s stock in a transaction that occurred on Friday, October 21st. The shares were acquired at an average price of $114.11 per share, for a total transaction of $99,846.25. Following the completion of the acquisition, the director now owns 26,520 shares of the company’s stock, valued at approximately $3,026,197.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.11% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Related posts

Leave a Comment